Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Auton Autacoid Pharmacol ; 27(1): 39-46, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17199874

RESUMEN

1. The effect of montelukast or MEN91507, selective leucotriene CysLT1 receptor antagonists, on antigen-induced airway inflammation and bronchoconstriction were compared in anaesthetized guinea-pigs. 2. In sensitized animals, ovalbumin (0.3 mg kg(-1), i.v.)-induced microvascular leakage in trachea, intrapulmonary airways, total lung (parenchyma and intrapulmonary airways) and urinary bladder was reduced by MEN91507 (0.01-1 micromol kg(-1), i.v.), whereas montelukast (0.01-1 micromol kg(-1), i.v.) antagonized the effect of the antigen only in the lung and urinary bladder. 3. Ovalbumin (1 mg kg(-1), i.v.)-induced bronchoconstriction was dose dependently antagonized by MEN91507 (10-30 micromol kg(-1), i.v.), whereas the effect of montelukast (0.1-30 micromol kg(-1), i.v.) was marginal (15-30% inhibition). Neither MEN91507 nor montelukast (30 micromol kg(-1), i.v.) affected the bronchoconstrictor response induced by acetylcholine (0.3 micromol kg(-1), i.v.) in sensitized animals. 4. It is concluded that montelukast and MEN91507 display a differential activity against the effect of endogenous leucotrienes, despite the fact that both compounds show a similar antagonist profile against exogenous leucotrienes acting through CysLT1 receptors.


Asunto(s)
Antígenos/inmunología , Broncoconstricción/efectos de los fármacos , Inflamación/inducido químicamente , Antagonistas de Leucotrieno/farmacología , Proteínas de la Membrana/antagonistas & inhibidores , Sistema Respiratorio/efectos de los fármacos , Sistema Respiratorio/patología , Acetatos/administración & dosificación , Acetatos/farmacología , Animales , Benzopiranos/farmacología , Ciclopropanos , Relación Dosis-Respuesta a Droga , Azul de Evans , Cobayas , Inflamación/patología , Inyecciones Intravenosas , Masculino , Ovalbúmina/administración & dosificación , Ovalbúmina/farmacología , Quinolinas/administración & dosificación , Quinolinas/farmacología , Receptores de Leucotrienos , Sistema Respiratorio/irrigación sanguínea , Sulfuros , Tetrazoles/farmacología
2.
Br J Pharmacol ; 161(7): 1616-27, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20726984

RESUMEN

BACKGROUND AND PURPOSE: Bradykinin, through its B(2) receptor, is involved in inflammatory processes related to arthropathies. In carrageenan and lipopolysaccharide (LPS)-induced arthritis in rat, the anti-inflammatory activity of MEN16132, a potent and selective kinin B(2) receptor antagonist, was compared with that of steroidal and nonsteroidal anti-inflammatory drugs. The interaction between MEN16132 and dexamethasone was also investigated. EXPERIMENTAL APPROACH: Drugs, alone or in combination, were injected into the knee joint 30min before intra-articular administration of carrageenan or LPS, in pentobarbital anaesthetized rats. Effects on incapacitation, oedema, neutrophil recruitment and kallikrein system activation, in the knee joint, were assessed. KEY RESULTS: MEN16132 and dexamethasone (10-300µg per knee) dose-dependently reduced carrageenan-induced joint pain, oedema and neutrophil infiltration, reaching a maximal inhibition of about 50%. Dexketoprofen exerted a similar analgesic activity, whereas it did not affect the other inflammatory responses. MEN16132 showed a partial inhibition of LPS-induced joint pain, whereas dexamethasone produced a full analgesic effect. Combination of MEN16132 and dexamethasone showed a strong synergistic interaction in inhibiting both carrageenan and LPS-induced knee joint inflammation. Dexamethasone did not prevent the contact activation of prekallikrein by carrageenan and the subsequent release of kallikreins and bradykinin in the synovium. CONCLUSIONS AND IMPLICATIONS: Steroids and kinin B(2) receptor antagonists appear to relieve arthritic symptoms induced by carrageenan or LPS and act synergistically to inhibit joint inflammation. This could have interesting therapeutic implications, possibly opening the way for combination therapies in the control of inflammatory arthropathies.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Artritis Experimental/tratamiento farmacológico , Antagonistas del Receptor de Bradiquinina B2 , Dexametasona/farmacología , Ornitina/análogos & derivados , Sulfonamidas/farmacología , Animales , Artritis Experimental/inducido químicamente , Artritis Experimental/metabolismo , Bradiquinina/metabolismo , Carragenina , Sinergismo Farmacológico , Inyecciones Intraarticulares , Calicreínas/sangre , Articulación de la Rodilla , Lipopolisacáridos , Masculino , Ornitina/farmacología , Peroxidasa/metabolismo , Ratas , Ratas Wistar , Receptor de Bradiquinina B2/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA